Composition comprising scirpusin A and scirpusin B and anti-adipogenesis/anti-obesity potential thereof

Patent metadata

Field	Value
Publication number	US-9387193-B2
Application number	US-201313944634-A
Country	US
Kind code	B2
Filing date	Jul 17, 2013
Priority date	Jul 18, 2012
Publication date	Jul 12, 2016
Grant date	Jul 12, 2016

Abstract

Disclosed is a composition comprising scirpusin A and scirpusin B and anti-obesity potential thereof. Also disclosed are methods of inhibiting adipogenesis using a composition comprising scirpusin A and scirpusin B. The present invention also disclosed methods of therapeutically managing obesity in mammals using a composition comprising scirpusin A and scirpusin B. Still further, the present invention also relates to a method of obtaining compositions comprising A. scirpusin A and scirpusin B and B. piceatannol and its dimers scirpusin A and scirpusin B through bioactivity guided fractionation of the rhizomes of Cyperus rotundus.

First claim

We claim:

1. A method of reducing adipogenesis in mammalian cells, said method comprising step of bringing to contact adipogenic mammalian cells with compositions derived by the bioactivity guided fractionation of the ethyl acetate extract of Cyperus rotundus rhizomes said compositions consisting essentially of A: scirpusin A and scirpusin B represented by STR#1 and STR#2 respectively or B: piceatannol and its dimers scirpusin A and scirpusin B represented by STR#1 and STR#2 respectively, and measuring reduced adipogenesis in said cells using the Oil Red O staining technique.

2. A method of therapeutically reducing obesity caused by high fat diet in mammals, said method comprising step of dietary supplementation of compositions derived by the bioactivity guided fractionation of the ethyl acetate extract of Cyperus rotundus rhizomes said compositions consisting essentially of A: scirpusin A and scirpusin B represented by STR#1 and STR#2 respectively or B: piceatannol and its dimers Scirpusin A and Scirpusin B represented by STR#1 and STR#2 respectively, to said mammals to bring about the effect of reduction in body weight.

3. A method of reducing adipogenesis in adipogenic mammalian cells comprising administering compositions derived by the bioactivity guided fractionation of the ethyl acetate extract of Cyperus rotundus rhizomes said compositions consisting essentially of A: scirpusin A and scirpusin B represented by STR#1 and STR#2 respectively or B: piceatannol and its dimers Scirpusin A and Scirpusin B represented by STR#1 and STR#2 respectively for reducing adipogenesis in mammalian cells said method comprising step of treating adipogenic mammalian cells (mammalian adipocytes) with effective concentration of said compositions to achieve the effect of reduction in adipogenesis.

4. A process for the bioactivity guided fractionation of the rhizomes of Cyperus rotundus to obtain anti-adipogenic/anti-obesity compositions comprising A: scirpusin A and scirpusin B represented by STR#1 and STR#2 and B: piceatannol and its dimers scirpusin A and scirpusin B represented by STR#1 and STR#2 respectively, said process comprising the steps of:
1—Drying the rhizomes of Cyperus rotundus and pulverizing the same to form a coarse powder;
2—Extracting the powder of step 1 with 3 volumes of hexane followed by heating, reflux for 3 hours and filtering to obtain the hexane soluble fraction and spent material;
3—Extracting the spent material of step 2 with 3 volumes of methanol followed by heating, reflux for 3 hours and filtering to obtain the methanol soluble active fraction and spent material;
4—Solubilizing the methanol soluble active fraction of step 3 in aqueous methanol and successively partitioning with chloroform (CHCl 3 ), Ethyl acetate (EtOAc) and methanol to obtain the chloroform layer, ethyl acetate layer and aqueous methanol layer respectively;
5—Subjecting the chloroform layer, ethyl acetate layer and the aqueous methanol layer to further bioactivity guided fractionation, wherein the bioactivity parameter is the ability of the chloroform layer, ethyl acetate layer and the aqueous methanol layer to inhibit adipogenesis in 3T3-L1 mouse adipocytes (mammalian adipocytes);
6—Calculating the IC 50 (μg/ml) values for adipogenesis inhibition exemplified by chloroform layer, ethyl acetate layer and the aqueous methanol layer (0, 9.39 and 66.42 respectively);
7—Fractionation of the ethyl acetate layer using column fractionation to identify the bioactivity (adipogenesis inhibition) biomarker, said fractionation includes the step where fractions are eluted with increasing polarity of methanol: chloroform to yield sub fractions of the ethyl acetate layer (fraction);
8—Subjecting the sub fractions of step 7 for bioactivity (anti-adipogenesis) analysis;
9—Identifying the most bioactive sub fractions of step 8 and subjecting the same to LC-MS analysis to identify the bioactive principles scirpusin A and scirpusin B; and
10—Subjecting sub fractions of step 7 through the preparative HPLC to obtain purified dimer and subjecting the same to High Resolution Mass Spectroscopy (HRMS), liquid chromatography-mass spectrometry (LC-MS/MS) and Nuclear Magnetic Resonance Spectroscopy (NMR) to confirm the mass and structures of scirpusin bioactive principles.

Assignees

• Majeed Muhammed
• Nagabhushanam Kalyanam
• Kalman Douglas
• Bhat Beena
• Vaidyanathan Priti
• Bani Sarang
• Pandey Anjali
• Sami Labs Ltd

Inventors

• Majeed Muhammed
• Nagabhushanam Kalyanam
• Kalman Douglas
• Bhat Beena
• Vaidyanathan Priti
• Bani Sarang
• Pandey Anjali

Classifications

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• A61K31/343 Primary

  condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone · CPC title

• A61K36/8905

  Cyperus (flatsedge) · CPC title